06:22 AM EDT, 05/19/2026 (MT Newswires) -- Bernstein revised its earnings estimates for Sonova (SOON.SW) after its fiscal 2026 results.

The research firm on Tuesday lifted its forecast for the Swiss hearing care company's EPS by 6% for fiscal 2027, trimming it by 2% and raising it by 1% for outyears.

"We maintain our Outperform [and price target of 248 francs] on Sonova, which we believe retains a current innovation lead in the hearing aid market,"analysts said. "In 2026/27E, we expect the company to benefit from its new platform launch in Wholesale and a new processor in Cochlear implants. We believe continued strength in Wholesale, despite challenging [comparables], and a gradual improvement in the underlying hearing aid market can drive a re-rating from almost 10-year lows."

Excluding the discontinued consumer hearing operations, revenue for the second half ended March 31 was up 5.9% in constant currency, while normalized EBITA was 16.4% higher, both in line with expectations. Sonova forecasts constant currency revenue growth of 5% to 8% and core EBIT growth of 7% to 10% for fiscal 2027.